Heavy Drinking Can Damage Every Part of the Eye
Jun 24, 2022 · Tori Rodriguez, MA, LPC, AHC, is an Atlanta-based journalist, licensed psychotherapist, and Ayurvedic health coach, creator of the body-positive wellness company Bettie Page Fitness, and author of 2 books – The Little Book of Bettie: Taking a Page from the Queen of Pinups and Bettie Page: The Lost Years.
Restoring the Retina: Coming Advancements to Repair Structure …
Feb 16, 2021 · The ophthalmic literature is replete with studies that open with frightening statistics on the rapid expansion of retinal diseases. Researchers frequently identify age-related macular degeneration (AMD) as the leading cause of blindness in the United States.
Photobiomodulation: An Emerging Dry AMD Treatment
Mar 20, 2024 · In exudative age-related macular degeneration (wet AMD), significant strides — such as the development of anti-vascular endothelial growth factor (anti-VEGF) therapies — have pushed the treatment possibilities forward and rewritten the likely course of the disease for many patients. However, for most patients, AMD is nonexudative (dry), and treatments for those patients remain largely ...
FDA Drug Approval Decisions Expected in December 2024
Nov 15, 2024 · The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval. The typical period for review is 10 months after the drug application has been accepted by the Agency.
Build A Safer Intravitreal Injection Protocol
Oct 7, 2022 · Intravitreal injections (IVI) have become one of the most common procedures in outpatient medicine, with an estimated 5.9 million performed in the United States in 2016. 1 IVI is an invaluable method of vision-saving drug delivery. Often, these medications are delivered repeatedly to patients in 1 or both eyes for the treatment of chronic retinal disease such as macular edema and ...
Ocular Myasthenia Gravis Treatment Options Explained
Jul 20, 2023 · Myasthenia gravis (MG) can occur in 2 forms: a generalized myasthenia gravis (GMG) or purely ocular myasthenia gravis (OMG). Ocular myasthenia gravis is characterized by progressive fatigability of skeletal muscle limited to the orbicularis oculi, levator palpebrae superioris, and the extraocular muscles. 1 Up to half of patients diagnosed with MG present with ocular muscle weakness before ...
Preservative-Free Sodium Hyaluronate Drop Improves Dry Eye for …
Nov 20, 2023 · Preservative-free sodium hyaluronate (0.4%) eye drops in different dosages effectively alleviates signs and symptoms of dye eye disease (DED) after 1 month of treatment in approximately 50% of patients, according to a study published in Clinical Ophthalmology.. Researchers investigated the effectiveness of the preservative-free sodium hyaluronate drops in a randomized, parallel assignment ...
Tolebrutinib Looks Promising for Patients With Non-Relapsing …
Oct 15, 2024 · Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study.
Photobiomodulation Treatment for Dry AMD Approved By FDA ...
Nov 15, 2024 · A photobiomodulation therapy device has received approval by the US Food and Drug Administration (FDA) to be marketed for the treatment of nonexudative (dry) age-related macular degeneration (AMD), according to statements from the FDA and the manufacturer.The device allows physicians the opportunity to offer a noninvasive treatment for dry AMD with a low-level laser therapy (LLLT) technology. 1,2
Low Dose Pilocarpine Drop Shows Strong Efficacy
Nov 12, 2024 · CSF-1, a low-dose, preservative-free, pilocarpine ophthalmic solution, consistently reduces pupil size and improves visual outcomes for patients with presbyopia, according to the results of the phase 3, NEAR-1 study (Near Eye-vision Acuity Restoration; ClinicalTrials.gov identifier: NCT04599933) and NEAR-2 (ClinicalTrials.gov identifier: NCT04599972) study.